A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cyclophosphamide) in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs CRS 207 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Cyclophosphamide
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 04 Apr 2019 Planned End Date changed from 1 Oct 2019 to 1 Oct 2023.
- 04 Apr 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2023.
- 31 Aug 2018 Biomarkers information updated